ReviewClinical pharmacology and therapeutics2026
Advances in Human Mass Balance Studies: An IQ Consortium Perspective on Current Practices and Emerging Trends.
Review in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human radiolabeled mass balance studies are crucial for comprehensively characterizing the absorption, distribution, metabolism, and excretion (ADME) of investigational drugs, providing essential data for drug development, regulatory evaluation, and product labeling. The IQ Consortium's Human Mass Balance Radiolabeled ADME (hADME) Working Group developed this perspective to address key considerations and highlight opportunities for these studies. This is particularly relevant as regulatory guidance, such as the 2024 US Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA), have finalized dedicated guidance documents, along with recommendations from other global regulatory bodies (including European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (of Japan; PMDA)); still, there are some regional differences. This review outlines current practices and emerging trends in hADME study design. It details seven clinical designs, from conventional radiolabeled approaches to microtracer studies that employ analytical techniques, such as accelerator mass spectrometry (AMS). It further highlights alternative non-radioactive approaches, including the use of Fluorine-19 nuclear magnetic resonance (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.